Whilst some GLP-1 receptor agonists have demonstrated cardiovascular benefits in clinical trials, patients with unstable angina, recent myocardial infarction, or severe heart failure should be evaluated by a cardiologist
Key Takeaways Tesamorelin is FDA-approved: it is the only GHRH analog with an approved indication for visceral fat reduction, giving it one of the best-documented clinical safety profiles among peptides
Aggressive Bulk (High Surplus or Dirty Bulk): This approach involves a larger calorie surplus , typically +500 to +1000+ calories above TDEE per day
The Zepbound tirzepatide benefits stem from this dual-action, which many studies indicate offers a superior and more profound impact on weight loss compared to single-action medications
However, the relationship seems to be complex, and researchers are still working to understand exactly how these medications and gut bacteria interact
Alzheimers Dement: J Alzheimers Association